A detailed history of Black Rock Inc. transactions in Merus N.V. stock. As of the latest transaction made, Black Rock Inc. holds 1,525,749 shares of MRUS stock, worth $69.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,525,749
Previous 1,467,924 3.94%
Holding current value
$69.3 Million
Previous $66.1 Million 36.58%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$39.81 - $60.2 $2.3 Million - $3.48 Million
57,825 Added 3.94%
1,525,749 $90.3 Million
Q1 2024

May 10, 2024

BUY
$28.03 - $51.82 $1.07 Million - $1.97 Million
38,031 Added 2.66%
1,467,924 $66.1 Million
Q4 2023

Feb 13, 2024

SELL
$20.06 - $28.66 $723,022 - $1.03 Million
-36,043 Reduced 2.46%
1,429,893 $39.3 Million
Q3 2023

Nov 13, 2023

BUY
$20.13 - $27.29 $5.64 Million - $7.64 Million
280,116 Added 23.62%
1,465,936 $34.6 Million
Q2 2023

Aug 11, 2023

BUY
$18.33 - $27.18 $10.7 Million - $15.9 Million
584,094 Added 97.07%
1,185,820 $31.2 Million
Q1 2023

May 12, 2023

SELL
$14.25 - $20.5 $447,948 - $644,417
-31,435 Reduced 4.96%
601,726 $11.1 Million
Q4 2022

Feb 13, 2023

BUY
$12.8 - $23.66 $1.43 Million - $2.65 Million
112,031 Added 21.5%
633,161 $9.8 Million
Q3 2022

Nov 14, 2022

SELL
$18.64 - $28.93 $342,938 - $532,254
-18,398 Reduced 3.41%
521,130 $10.4 Million
Q2 2022

Aug 12, 2022

BUY
$13.98 - $29.25 $38,137 - $79,794
2,728 Added 0.51%
539,528 $12.2 Million
Q1 2022

May 12, 2022

SELL
$23.58 - $30.91 $3.79 Million - $4.97 Million
-160,822 Reduced 23.05%
536,800 $14.2 Million
Q4 2021

Feb 10, 2022

BUY
$20.0 - $32.29 $8.37 Million - $13.5 Million
418,306 Added 149.76%
697,622 $22.2 Million
Q3 2021

Nov 09, 2021

BUY
$16.48 - $27.23 $457,155 - $755,360
27,740 Added 11.03%
279,316 $6.14 Million
Q2 2021

Aug 11, 2021

BUY
$20.0 - $25.48 $5.03 Million - $6.41 Million
251,576 New
251,576 $5.3 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.08B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.